4-(3-羟基丙基)-1-哌嗪羧酸乙酯 | 7483-27-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(3-羟基丙基)-1-哌嗪羧酸乙酯
• 英文名称: 4-(3-hydroxypropyl)piperazinylcarboxylic acid ethyl ester
• 英文别名: ethyl 4-(3-hydroxypropyl)piperazine-1-carboxylate；4-(3-hydroxy-propyl)-piperazine-1-carboxylic acid ethyl ester；1-(Ethoxycarbonyl)-4-(3-hydroxy-propyl)-piperazin；N-(3-Hydroxy-1-propyl)-N'-carbethoxypiperazin
• CAS: 7483-27-4
• 化学式: C₁₀H₂₀N₂O₃
• mdl: MFCD13176500
• 分子量: 216.28
• InChiKey: JNANLGAZMJOZBL-UHFFFAOYSA-N

物化性质

• 沸点：
  142 °C(Press: 0.4 Torr)
• 密度：
  1.113±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  53
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(3-羟基丙基)-1-哌嗪羧酸乙酯 在 水 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 1-哌嗪基丙醇
  参考文献：
  名称：

  Pharmacophore-based design, synthesis, and biological evaluation of novel chloro-pyridazine piperazines as human rhinovirus (HRV-3) inhibitors

  摘要：

  A series of chloro-pyridazine piperazines were developed based on the structure of human rhinovirus (HRV) capsid-binding inhibitors with proven activity using a pharmacophore model. A preliminary evaluation demonstrated potent activity against HRV-3 with low cytotoxicity. A docking analysis indicated that 8a could fit into, and form tight interactions (e. g., H-bonds, sigma-pi effect) with the active site in VP1. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.001
• 作为产物：
  描述：

  N-哌嗪甲酸乙酯 、 3-溴-1-丙醇 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 以76.3%的产率得到4-(3-羟基丙基)-1-哌嗪羧酸乙酯
  参考文献：
  名称：

  PYRIDAZINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR TREATING MICRORNA VIRAL INFECTION

  摘要：

  公开号：

  EP2602252B1

文献信息

• N-Alkylated 1,4-Dihydropyridines: New Agents to Overcome Multidrug Resistance.
  作者：Koji OHSUMI、Kazuo OHISHI、Yoshihiro MORINAGA、Ryusuke NAKAGAWA、Yasuyo SUGA、Takaaki SEKIYAMA、Yukio AKIYAMA、Takashi TSUJI、Takashi TSURUO

  DOI：10.1248/cpb.43.818

  日期：——

  New N-alkylated 1, 4-dihydropyridine derivatives were synthesized and their ability to overcome multidrug resistance was examined in vincristine-resistant P388 cells (P388/VCR cells). Compounds that possessed an arylalkyl substituent on the dihydropyridine ring nitrogen were more potent than verapamil in potentiating the cytotoxicity of vincristine against P388/VCR cells. However, neither drug effectively enhanced the antitumor activity of vincristine in tumor-bearing mice. Introduction of basic nitrogen-containing substituents on the side chain of 1, 4-dihydropyridines gave improved activity in vitro and in vivo. The piperazine derivative 12c and 12o were more than 10 times as potent as verapamil in vitro. Four compounds selected for in vivo testing showed superior antitumor activity in P388/VCR-bearing mice in combination with vincristine. The structure-activity relationships of the compounds are discussed.

  新合成的N-烷基化1,4-二氢吡啶衍生物，在长春新碱耐药的P388细胞（P388/VCR细胞）中检测了其克服多药耐药的能力。在二氢吡啶环氮上带有芳烷基取代基的化合物，比维拉帕米更能增强长春新碱对P388/VCR细胞的细胞毒性。然而，这两种药物均未有效地增强长春新碱在携带肿瘤的小鼠中的抗肿瘤活性。在1,4-二氢吡啶的侧链上引入含有碱性氮的取代基，在体外和体内均能提高活性。哌嗪衍生物12c和12o在体外比维拉帕米强10倍以上。选出四种化合物进行体内测试，它们与长春新碱联合使用时，在携带P388/VCR的肿瘤小鼠中显示出优越的抗肿瘤活性。讨论了化合物的构效关系。
• Pyridazine derivatives and use thereof as medicaments for treating microRNA viral infection
  申请人：Li Song

  公开号：US08846678B2

  公开（公告）日：2014-09-30

  Disclosed are pyridazine derivatives represented by Formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, methods of treating and/or preventing diseases or disorders associated with viral infections in patients using the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by Formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification.

  本发明涉及由公式I表示的吡嗪衍生物或其药学上可接受的盐或水合物，包含该化合物的制药组合物，使用该化合物治疗和/或预防患有病毒感染相关疾病或障碍的患者的方法，以及使用该化合物制备治疗和/或预防病毒感染相关疾病或障碍的药物。公式I所表示的化合物具有抗病毒活性，特别是抗微RNA病毒活性。所述化合物中的符号在说明书中描述。
• Non-imidazole histamine NO-donor H3-antagonists
  作者：Paolo Tosco、Massimo Bertinaria、Antonella Di Stilo、Clara Cena、Roberta Fruttero、Alberto Gasco

  DOI：10.1016/j.farmac.2005.04.007

  日期：2005.6

  Recently a series of H3-antagonists related to Imoproxifan was realised (I); in these products the oxime substructure of the lead was constrained in NO-donor furoxan systems and in the corresponding furazan derivatives. In this paper, a new series of compounds derived from I by substituting the imidazole ring with the ethoxycarbonylpiperazino moiety present in the non-imidazole H3-ligand A-923 is described. For all the products synthesis and preliminary pharmacological characterisation, as well as their hydrophilic-lipophilic balance, are reported. The imidazole ring replacement generally results in a decreased H3-antagonist activity with respect to the analogues of series I and, in some cases, induces relaxing effects on the electrically contracted guinea-pig ileum, probably due to increased affinity for other receptor systems.
• Pyrazole derivatives as new potent and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors
  作者：Toshio Nakamura、Hiroyuki Kakinuma、Hideaki Amada、Noriyuki Miyata、Kazuo Taniguchi、Ayumi Koda、Masakazu Sato

  DOI：10.1016/j.bmc.2004.08.047

  日期：2004.12

  Improvement of the physical properties of pyrazole derivative 1, which we reported previously as a potent and selective 20-HETE synthase inhibitor (IC50 5.7nM), is described. Introduction of a sufficient substituted-amino group on the side chain enhanced the water-solubility of 1 (0.014mg/mL at pH6.8). Among the products, 2-piperazinoethoxy derivatives 3e and 6b showed solubility suitable for injection and potent inhibitory activity toward 20-HETE synthase (IC50 21.2 and 14.0 nM, respectively). (C) 2004 Elsevier Ltd. All rights reserved.
• PYRIDAZINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR TREATING MICRORNA VIRAL INFECTION
  申请人：Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China

  公开号：EP2602252B1

  公开（公告）日：2016-05-04